View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsPMD Device Solutions 将来の成長Future 基準チェック /26 PMD Device Solutionsは収益が増加すると予測されています。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長22.7%収益成長率50.9%将来の株主資本利益率n/aアナリストカバレッジLow最終更新日03 Dec 2024今後の成長に関する最新情報お知らせ • Jun 26PMD Device Solutions AB Revises Earnings Guidance for the Year 2026PMD Device Solutions AB revised earnings guidance for the year 2026. The company revised its annual recurring revenue (ARR) target from SEK 100 million to SEK 260 million by yearend 2026. The increase is driven by the current strong business activity in the UK and the acquisition and subsequent restructuring of the US remote patient monitoring company. PMDS initially forecasted SEK 100 million of annual recurring revenue as part of its listing in January 2024.すべての更新を表示Recent updatesNew Risk • Nov 07New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-kr115m). Market cap is less than US$10m (€5.17m market cap, or US$5.55m). Minor Risks Less than 3 years of financial data is available. Revenue is less than US$5m (kr40m revenue, or US$3.7m).お知らせ • Oct 29PMD Device Solutions AB Approves Board ChangesPMD Device Solutions AB at its EGM held on October 29, 2024 approved that the board of directors shall consist of Martin Roos (new election) and Sten Dahlborg (new election). It was further resolved to elect Sten Dahlborg as chairman of the board. Peter Donnelly therefore resigns as member of the board as well as chairman. Martin Roos: Martin Roos is an INSEAD certified board director (IDP) with board and executive experience from telecom, tech and biotech. He currently serves as the chairman for Seamless Distribution Systems and is a board member of Nexam Chemicals and Redsense Medical (listed on NGM Nordic SME, Nasdaq First North and Spotlight respectively). He also serves on the board of startups such as Lignin Industries. Martin has previously served on the board operating committee of WOM in Chile and was the CEO for Cable and Wireless Caribbean and Altice in the Dominican Republic (integrating Orange with Tricom), in addition to senior leadership positions with Ericsson. During his tenure at Cable and Wireless, Martin also served on the Board of Directors of TSTT in Trinidad and Tobago. Martin holds an MSc in Economics from Stockholm School of Economics, a MSc in Chemical Engineering from The Royal Institute of Technology in Stockholm. Sten Dahlborg: Sten Dahlborg is an accomplished executive with over 20 years of experience in the Medtech industry and investment management. He has served as the chairman and managing director of several companies, including Ascilion and CGI Healthcare, where he successfully led strategic exits and business development initiatives. As a business advisor and board member for various medical technology firms, he has played a pivotal role in fostering innovation and commercialization within the sector. Currently, Sten is the CEO of CGI Ventures AB, advising new businesses on strategic growth and mergers and acquisitions, and serves as a co-owner of CITRUS MÉXICO. His expertise in adaptive leadership and investment management, coupled with a strong focus on commercial success, positions him as a leader in driving advancements in healthcare technology.お知らせ • Oct 11PMD Device Solutions Announces Board and Executive ChangesPMD Device Solutions announced that its largest founding shareholder, Miman Ventures AB, has requested the Board of PMDS to convene an Extraordinary General Meeting (EGM) to appoint new Non-Executive Directors. This request follows recent management changes and forms part of a broader transition in the company's governance and operational structure. The company has recently seen the resignation of Magnus Christensen, Christer Ahlberg, and Anne Dorney. Anne, who has been an Executive Director, will also be retiring with immediate effect from her role as Chief Compliance Officer. In light of these departures, PMDS will actively engage in appointing new individuals who will support the company's continued growth.Reported Earnings • Aug 23Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: kr12.4m (up 2.6% from 2Q 2023). Net loss: kr11.7m (loss widened 85% from 2Q 2023). Revenue is forecast to grow 50% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in Europe.お知らせ • Jun 26PMD Device Solutions AB Revises Earnings Guidance for the Year 2026PMD Device Solutions AB revised earnings guidance for the year 2026. The company revised its annual recurring revenue (ARR) target from SEK 100 million to SEK 260 million by yearend 2026. The increase is driven by the current strong business activity in the UK and the acquisition and subsequent restructuring of the US remote patient monitoring company. PMDS initially forecasted SEK 100 million of annual recurring revenue as part of its listing in January 2024.New Risk • Jun 10New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr18m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr18m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Negative equity (-kr106m). Minor Risks Less than 3 years of financial data is available. Revenue is less than US$5m (kr37m revenue, or US$3.5m). Market cap is less than US$100m (€12.9m market cap, or US$13.9m).お知らせ • Apr 09PMD Device Solutions AB (OM:PMDS) intends to acquire Coala Life Inc. from Coala-Life Group AB (publ).PMD Device Solutions AB (OM:PMDS) intends to acquire Coala Life Inc. from Coala-Life Group AB (publ) on April 9, 2024. On March 22, 2024, the Board of Directors of Coala Life filed for bankruptcy. The transaction will be closed no later than April 10th, 2024.お知らせ • Mar 01+ 4 more updatesPMD Device Solutions AB to Report Nine Months, 2024 Results on Nov 22, 2024PMD Device Solutions AB announced that they will report nine months, 2024 results on Nov 22, 2024お知らせ • Jan 24PMD Device Solutions AB to Report Fiscal Year 2023 Results on Feb 29, 2024PMD Device Solutions AB announced that they will report fiscal year 2023 results on Feb 29, 2024業績と収益の成長予測DB:8T00 - アナリストの将来予測と過去の財務データ ( )SEK Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2027203N/AN/AN/A112/31/2026124N/A-75112/31/202575N/A-10N/A112/31/202442N/A-17-1419/30/202439-48-35-33N/A6/30/202440-44-15-14N/A3/31/202437-39-18-16N/A12/31/202338-39-22-18N/A3/31/202318-3615N/Aアナリストによる今後の成長予測収入対貯蓄率: 8T00の予測収益成長が 貯蓄率 ( 1% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 8T00の収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 8T00の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 8T00の収益 ( 50.9% ) German市場 ( 6.8% ) よりも速いペースで成長すると予測されています。高い収益成長: 8T00の収益 ( 50.9% ) 20%よりも速いペースで成長すると予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 8T00の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/01/16 19:14終値2024/12/23 00:00収益2024/09/30年間収益2023/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋PMD Device Solutions AB 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Johan UnnerusRedeye
お知らせ • Jun 26PMD Device Solutions AB Revises Earnings Guidance for the Year 2026PMD Device Solutions AB revised earnings guidance for the year 2026. The company revised its annual recurring revenue (ARR) target from SEK 100 million to SEK 260 million by yearend 2026. The increase is driven by the current strong business activity in the UK and the acquisition and subsequent restructuring of the US remote patient monitoring company. PMDS initially forecasted SEK 100 million of annual recurring revenue as part of its listing in January 2024.
New Risk • Nov 07New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-kr115m). Market cap is less than US$10m (€5.17m market cap, or US$5.55m). Minor Risks Less than 3 years of financial data is available. Revenue is less than US$5m (kr40m revenue, or US$3.7m).
お知らせ • Oct 29PMD Device Solutions AB Approves Board ChangesPMD Device Solutions AB at its EGM held on October 29, 2024 approved that the board of directors shall consist of Martin Roos (new election) and Sten Dahlborg (new election). It was further resolved to elect Sten Dahlborg as chairman of the board. Peter Donnelly therefore resigns as member of the board as well as chairman. Martin Roos: Martin Roos is an INSEAD certified board director (IDP) with board and executive experience from telecom, tech and biotech. He currently serves as the chairman for Seamless Distribution Systems and is a board member of Nexam Chemicals and Redsense Medical (listed on NGM Nordic SME, Nasdaq First North and Spotlight respectively). He also serves on the board of startups such as Lignin Industries. Martin has previously served on the board operating committee of WOM in Chile and was the CEO for Cable and Wireless Caribbean and Altice in the Dominican Republic (integrating Orange with Tricom), in addition to senior leadership positions with Ericsson. During his tenure at Cable and Wireless, Martin also served on the Board of Directors of TSTT in Trinidad and Tobago. Martin holds an MSc in Economics from Stockholm School of Economics, a MSc in Chemical Engineering from The Royal Institute of Technology in Stockholm. Sten Dahlborg: Sten Dahlborg is an accomplished executive with over 20 years of experience in the Medtech industry and investment management. He has served as the chairman and managing director of several companies, including Ascilion and CGI Healthcare, where he successfully led strategic exits and business development initiatives. As a business advisor and board member for various medical technology firms, he has played a pivotal role in fostering innovation and commercialization within the sector. Currently, Sten is the CEO of CGI Ventures AB, advising new businesses on strategic growth and mergers and acquisitions, and serves as a co-owner of CITRUS MÉXICO. His expertise in adaptive leadership and investment management, coupled with a strong focus on commercial success, positions him as a leader in driving advancements in healthcare technology.
お知らせ • Oct 11PMD Device Solutions Announces Board and Executive ChangesPMD Device Solutions announced that its largest founding shareholder, Miman Ventures AB, has requested the Board of PMDS to convene an Extraordinary General Meeting (EGM) to appoint new Non-Executive Directors. This request follows recent management changes and forms part of a broader transition in the company's governance and operational structure. The company has recently seen the resignation of Magnus Christensen, Christer Ahlberg, and Anne Dorney. Anne, who has been an Executive Director, will also be retiring with immediate effect from her role as Chief Compliance Officer. In light of these departures, PMDS will actively engage in appointing new individuals who will support the company's continued growth.
Reported Earnings • Aug 23Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: kr12.4m (up 2.6% from 2Q 2023). Net loss: kr11.7m (loss widened 85% from 2Q 2023). Revenue is forecast to grow 50% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in Europe.
お知らせ • Jun 26PMD Device Solutions AB Revises Earnings Guidance for the Year 2026PMD Device Solutions AB revised earnings guidance for the year 2026. The company revised its annual recurring revenue (ARR) target from SEK 100 million to SEK 260 million by yearend 2026. The increase is driven by the current strong business activity in the UK and the acquisition and subsequent restructuring of the US remote patient monitoring company. PMDS initially forecasted SEK 100 million of annual recurring revenue as part of its listing in January 2024.
New Risk • Jun 10New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr18m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr18m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Negative equity (-kr106m). Minor Risks Less than 3 years of financial data is available. Revenue is less than US$5m (kr37m revenue, or US$3.5m). Market cap is less than US$100m (€12.9m market cap, or US$13.9m).
お知らせ • Apr 09PMD Device Solutions AB (OM:PMDS) intends to acquire Coala Life Inc. from Coala-Life Group AB (publ).PMD Device Solutions AB (OM:PMDS) intends to acquire Coala Life Inc. from Coala-Life Group AB (publ) on April 9, 2024. On March 22, 2024, the Board of Directors of Coala Life filed for bankruptcy. The transaction will be closed no later than April 10th, 2024.
お知らせ • Mar 01+ 4 more updatesPMD Device Solutions AB to Report Nine Months, 2024 Results on Nov 22, 2024PMD Device Solutions AB announced that they will report nine months, 2024 results on Nov 22, 2024
お知らせ • Jan 24PMD Device Solutions AB to Report Fiscal Year 2023 Results on Feb 29, 2024PMD Device Solutions AB announced that they will report fiscal year 2023 results on Feb 29, 2024